Clinical trials: Anlotinib
Gastric Cancer
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.
- Trial name
- NCT02461407
- Testing
- Anlotinib
- Where
- 38 sites in China
- Volunteers
- 378 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
Evaluate the efficacy and safety of Anlotinib as the 3-line treatment of patients with advanced non-small lung cancer, with placebo control.
- Trial name
- ALTER0303 (NCT02388919)
- Testing
- Anlotinib
- Where
- 40 sites in China
- Volunteers
- 439 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cancer
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics.To further study the pharmacokinetic characteristics of Anlotinib in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT02752516
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Soft Tissue Sarcoma
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.
- Trial name
- NCT02449343
- Testing
- Anlotinib
- Where
- 25 sites in China
- Volunteers
- 233 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
1. To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the phase II study of anlotinib in patients with advanced non-small cell lung cancer. 2.
- Trial name
- NCT02029209
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
- Trial name
- ALTER0802 (NCT02809534)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Anlotinib, RCC
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT02072031
- Testing
- Anlotinib, Sunitinib maleate
- Where
- 15 sites in China
- Volunteers
- 133 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- ALTN (NCT01833923)
- Testing
- anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT01924195
- Testing
- Anlotinib
- Where
- 13 sites in China
- Volunteers
- 117 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.